Molecular Biomedicine (May 2021)

Correction to: Development of a novel TLR8 agonist for cancer immunotherapy

Yuxun Wang,
Heping Yang,
Huanping Li,
Shuda Zhao,
Yikun Zeng,
Panpan Zhang,
Xiaoqin Lin,
Xiaoxiang Sun,
Longsheng Wang,
Guangliang Fu,
Yaqiao Gao,
Pei Wang,
Daxin Gao

Affiliations

Yuxun Wang: Shanghai Denovo Pharmatech Co., Ltd.
Heping Yang: Shanghai Denovo Pharmatech Co., Ltd.
Huanping Li: Shanghai Denovo Pharmatech Co., Ltd.
Shuda Zhao: Shanghai Denovo Pharmatech Co., Ltd.
Yikun Zeng: Shanghai Denovo Pharmatech Co., Ltd.
Panpan Zhang: Shanghai Denovo Pharmatech Co., Ltd.
Xiaoqin Lin: Shanghai Denovo Pharmatech Co., Ltd.
Xiaoxiang Sun: Shanghai Denovo Pharmatech Co., Ltd.
Longsheng Wang: Shanghai Denovo Pharmatech Co., Ltd.
Guangliang Fu: Shanghai Denovo Pharmatech Co., Ltd.
Yaqiao Gao: Shanghai Denovo Pharmatech Co., Ltd.
Pei Wang: Shanghai Denovo Pharmatech Co., Ltd.
Daxin Gao: Shanghai Denovo Pharmatech Co., Ltd.

DOI: https://doi.org/10.1186/s43556-021-00042-3
Journal volume & issue: Vol. 2, no. 1
pp. 1 – 1

Abstract

No abstracts available.

Published in Molecular Biomedicine

ISSN: 2662-8651 (Online)
Publisher: Springer
Country of publisher: Switzerland
LCC subjects: Medicine
Website: https://www.springer.com/journal/43556

About the journal